Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
BeiGene Australia Pty Ltd
This is a non-randomised trial trial with two parts in people with B-Cell Malignancies including Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, and Waldenström Macroglobulinemia. In Part 1 (Monotherapy Dose Finding) participants will receive BGB-16673 administered as a once daily regimen. In Part 2 (two Expansion cohorts) BGB-16673 will also be administered as a once daily regimen.